ARCH Venture Management, LLC
13F filer · CIK 0001274403Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.1BU.S. long equity reported on 13F
Positions123 new · 1 closed
Net flow last quarter+$313MBuys minus sells
Top 10 positions weight99.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202612 positions | |||||
| $176M | 15.95% | 5.26% | New | Q2 2026 | |
| $156M | 14.16% | 4.40% | Not reported | Q2 2024 | |
| $155M | 14.12% | 7.78% | Not reported | Q2 2024 | |
| $137M | 12.42% | 11.76% | New | Q2 2026 | |
| $130M | 11.81% | 2.27% | Not reported | Q4 2021 | |
| $129M | 11.76% | 7.50% | -1.7% | Q2 2025 | |
| $123M | 11.18% | 7.42% | Not reported | Q1 2025 | |
| $45.5M | 4.14% | 13.88% | Not reported | Q2 2025 | |
| $32.8M | 2.98% | 1.52% | Not reported | Q1 2026 | |
| $8.35M | 0.76% | 0.17% | Not reported | Q4 2025 | |
| $6.74M | 0.61% | 11.99% | New | Q2 2026 | |
| $1.33M | 0.12% | 1.65% | Not reported | Q3 2023 | |
| Q1 2026Reported May 15, 202610 positions | |||||
| $123M | 18.16% | 8.28% | Not reported | Q1 2025 | |
| $117M | 17.23% | 7.80% | Not reported | Q2 2024 | |
| $116M | 17.09% | 8.01% | Not reported | Q2 2025 | |
| $115M | 16.95% | 2.28% | -35.9% | Q4 2021 | |
| $108M | 15.98% | 4.42% | Not reported | Q2 2024 | |
| $65.1M | 9.62% | 13.92% | +17.7% | Q2 2025 | |
| $24.3M | 3.59% | 1.52% | New | Q1 2026 | |
| $4.62M | 0.68% | 0.17% | -70.5% | Q4 2025 | |
| $2.65M | 0.39% | 3.43% | Not reported | Q3 2023 | |
| $2.06M | 0.30% | 2.19% | Not reported | Q1 2024 | |
| Q4 2025Reported Feb 17, 20269 positions | |||||
| $171M | 26.19% | 8.35% | Not reported | Q1 2025 | |
| $126M | 19.31% | 4.46% | Not reported | Q2 2024 | |
| $113M | 17.36% | 7.81% | Not reported | Q2 2024 | |
| $84.9M | 13.03% | 12.98% | Not reported | Q2 2025 | |
| $77.9M | 11.95% | 9.26% | Not reported | Q2 2025 | |
| $41.1M | 6.31% | 3.89% | Not reported | Q4 2021 | |
| $25M | 3.83% | 3.45% | Not reported | Q3 2023 | |
| $12M | 1.85% | 0.58% | New | Q4 2025 | |
| $1.06M | 0.16% | 2.49% | Not reported | Q1 2024 | |
| Q3 2025Reported Nov 14, 20259 positions | |||||
| $111M | 22.49% | 7.83% | Not reported | Q2 2024 | |
| $110M | 22.38% | 4.48% | Not reported | Q2 2024 | |
| $107M | 21.70% | 8.57% | Not reported | Q1 2025 | |
| $73.8M | 14.98% | 9.29% | Not reported | Q2 2025 | |
| $44.8M | 9.10% | 14.30% | +51.5% | Q2 2025 | |
| $24.1M | 4.89% | 3.90% | Not reported | Q4 2021 | |
| $21.2M | 4.30% | 3.48% | Not reported | Q3 2023 | |
| $635K | 0.13% | 2.60% | Not reported | Q1 2024 | |
| CTCEROCero Therapeutics Holdings, Inc. | $114K | 0.02% | 1.86% | Not reported | Q1 2024 |
Premium opens every quarter this fund has filed